Navigation Links
Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease
Date:6/22/2009

assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential that data from the phase 3 trial design for Amigal is insufficient to support regulatory approval; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials and studies may not be predictive of future results. Additionally, all forward looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
2. Amicus Therapeutics Announces Plans to Present Phase 1 Data for AT2220 for Pompe Disease
3. Amicus Therapeutics Announces Positive Results From Two Phase 1 Clinical Studies of AT2220 for Pompe Disease
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Amicus Therapeutics Presents Data from Clinical Ex Vivo Response Study and Phase 1 Studies of AT2220
6. Amicus Therapeutics Begins Phase 2 Clinical Trial of AT2220 in Pompe Disease
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Amicus Therapeutics Announces Second Quarter 2008 Financial Results
9. Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009
10. Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease
11. Amicus Therapeutics Announces Issuance of New Plicera(TM) Composition of Matter Patent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... July 23, 2014  Researchers from the North American ... elevates calcium levels too high, 1 putting ... problems. Women close to menopause are commonly ... to prevent diseases such as osteoporosis, to which they ... women determine how much calcium they typically get through ...
(Date:7/23/2014)... This September leading clinicians in orthodontics and ... for DOCtalk 2014 —a "Dynamic Orthodontic ... and private practitioner Dr. David Sarver , DOCtalk ... clinical and practice management efficiency and high quality patient ... to welcome fresh thinking and join a community of ...
(Date:7/23/2014)... , July 23 2014 Ampio Pharmaceuticals, ... its new headquarters, manufacturing and research facility: ... 80112 Direct: (720) 437-6500 ... efficient, pharmaceutical drug manufacturing facility will be fully operational ... the first batches of Ampion TM necessary to ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 22014 DOCtalk Registration Now Open 22014 DOCtalk Registration Now Open 3Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado 2
... 2011 Assured Pharmacy (Pink Sheets: APHY ), ... than 3,000 sufferers of chronic pain announced that total sales ... 2010 were $1,514,984 which equates to $70,464 per business day. ... total sales of $1,348,344 for December 2009 which equates to ...
... 2011 BioDelivery Sciences International, Inc. ... outcome of a pre-Investigational New Drug (pre-IND) meeting ... on the development program for BEMA Buprenorphine/Naloxone, BDSI,s ... discussed is based on pharmacokinetic and safety data ...
Cached Medicine Technology:Assured Pharmacy Reports Same Store Sales for the Month of December 2010 2Assured Pharmacy Reports Same Store Sales for the Month of December 2010 3BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 2BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting 3
(Date:7/23/2014)... 2014 The European Vitamins Market report ... analysis and projection of revenue. The market in Europe ... 2012 to $1,202.08 million by 2018, at a CAGR ... the TOC of the European Vitamins Market report, to ... also provides a glimpse of the segmentation in the ...
(Date:7/23/2014)... RFcnn.com, a distinguished electrical equipment retailer, has ... . What’s more, the company has decided to provide big ... who place an order for the company’s brand new SMA ... , The high quality SMA JACK from RFcnn.com Provides ... superb quality electrical equipment to help make things much easier ...
(Date:7/23/2014)... 23, 2014 "I wanted a better way ... as my blood sugar, blood pressure and pulse rate," said ... to have to carry along a bunch of different devices, ... He developed the Master III to make it easier to ... one convenient unit. The accessory enables the user to have ...
(Date:7/23/2014)... hued dyes, George Mason University researchers discovered an ... other, possibly leading to new treatments for cancer, ... George Mason researchers unraveled the mystery of deciphering ... "One protein interlocks with another protein like adjacent ... a signal down the line to the next ...
(Date:7/23/2014)... According to a new market research report of ... IP, SOC IP), Design Architecture (Hard IP, Soft IP), ... - Forecast & Analysis to 2013 - 2020", the ... a CAGR of 12.6% from 2014 to 2020 and ... 76 market data tables with 60 figures spread through ...
Breaking Medicine News(10 mins):Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Vitamins (Nutraceuticals) Market is Expected to Reach $1,202.08 Million in 2018 - New Report by MicroMarket Monitor 5Health News:New Collection of SMA JACK Released by China Electrical Accessory Manufacturer RFcnn 2Health News:Researchers unlock the protein puzzle 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 5Health News:Semiconductor IP Market Estimated to Reach $5.63 Billion by 2020 – New Report by MarketsandMarkets 6
... who receive higher disability ratings for work-related back injuries ... those who get lower ratings.// ,This ... relationship between Workers’ Compensation settlements for back pain and ... showing ‘blacks receive less treatment for their back pain ...
... Researchers at Mayo Clinic have successfully isolated nanoparticles from ... RNA and DNA that appear to be associated with ... December issue of the Journal of Investigative Medicine, are ... the mystery of whether nanoparticles are viable living forms ...
... have a genetic predisposition. //This study is lead by ... helix. ,Collaborated Research is being launched by Researchers ... Institute for Medical Research and Cold Spring Harbor Laboratory ... ,"For complex illnesses like bipolar disorder that vary dramatically ...
... but a medical aberration until recently—are now becoming a ... that has pediatricians at the Johns Hopkins Children’s Center, ... doctors have yet to quantify the precise increase and ... play some role—pediatricians agree that too much salt and ...
... welcomed the first formal agreement to deliver a fast, ... move as a win for patients and doctors alike. ... first organisation to sign up to deliver the new ... immediately after paying the doctor’s bill. ,The ...
... woman succumbed to bird flu.// With this, the total number of ... since March 2006. ,The woman aged 30 years had ... detected with H5N1 barely a few hours before she died. Though ... since mid- December, Doctors had not checked her out for ...
Cached Medicine News:Health News:Is Workers’ Comp. Settlements for Back Pain Fair 2Health News:Link Between Nanoparticles and Kidney Stones 2Health News:Link Between Nanoparticles and Kidney Stones 3Health News:Research on Bipolar Disorder Launched 2Health News:Kidney Stones Occurring More Often in Children 2